Based on these findings, we hypothesized that dysregulated CDK1 activation in cancer cells may trigger aberrant BRD4 hyperphosphorylation that persists outside of mitosis, supporting stronger chromatin binding and aberrant induction of its mitotic-bookmarked oncogenes, thereby driving tumor growth and BETi resistance. This evidence concerns the gene CDK1 and cancer.